Systematic review of clinical trials reveals low adherence to guidelines on outcomes in immune thrombocytopenia, suggesting variability may hinder evidence synthesis.
Key Points
Only 20.3% of primary outcomes in trials for immune thrombocytopenia adhered to established guidelines.
The majority of included trials were phase 3 and randomized, predominantly conducted in China.
Clinical trials frequently lacked clear diagnostic criteria and had inconsistent outcome definitions.
Widespread variability in outcome definitions complicates evidence synthesis in immune thrombocytopenia research.
Cite This Study
David Gómez‐Almaguer (2025) studied this question.